We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Major Major

2 July 2014 By Robert Cyran

It’s snapping up Seragon for at least $725 mln. CEO Richard Heyman only set up the one-drug biotech firm a year ago, spinning it out before getting $650 mln from J&J for its parent company. With pharma giants desperate for new product, such deal-making is likely to be replicated.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)